Age/Race Differences in HER2 Testing and in Incidence Rates for Breast Cancer Triple Subtypes A Population-Based Study and First Report
Age/Race Differences in HER2 Testing and in Incidence Rates for Breast Cancer Triple Subtypes A Population-Based Study and First Report
复制标题
DOI：
10.1002/cncr.25016
复制
发表时间：
2010-06-01
期刊：
影响因子：
6.2
通讯作者：
Eley, J. William
中科院分区：
文献类型：
--
作者：
Lund, Mary Jo;Butler, Ebonee N.;Eley, J. William
背景：尽管美国 2000 年指南建议通过人表皮生长因子受体 2 (HER2) 来表征乳腺癌，但国家癌症登记处并不收集 HER2，因此基于人群对 HER2 和临床“三重亚型”（雌激素受体 [ER]/孕激素受体 [PR]/HER2）的了解在很大程度上是未知的。我们记录了基于人群的 HER2 检测/状态、三重亚型的患病率，并提出了亚型发病率的第一份报告。方法：对 2003 年至 2004 年期间被诊断患有乳腺癌的 1842 名亚特兰大大都市女性的病历进行了 HER2 检索。按年龄、种族/民族、肿瘤因素、社会经济状况和治疗对 HER2 检测/状态和三重亚型进行分析。计算年龄调整后的发病率。结果：超过 90% 的病例接受了 HER2 检测：12.6% 呈阳性，71.7% 呈阴性，15.7% 未知。对于年轻女性、白种人或非裔美国人血统或被诊断患有早期疾病的女性来说，HER2 检测依从性明显更好。 HER2+肿瘤的发病率（每10万人）为21.1，三阴性肿瘤为27.8，后者因种族而异（黑人和白人女性分别为36.3和19.4）。结论：HER2 建议并未得到一致遵守。乳腺癌三重亚型的发病率因年龄/种族而异。随着生物学知识转化为临床环境，例如 HER2 作为生物标志物，国家癌症登记处将有责任报告此信息。发病率谨慎地推断，黑人和白人女性的 HER2+ 肿瘤每年负担分别为 3000 例和 17,000 例，三阴性肿瘤分别为 5000 例和 16,000 例。检测、率和负担变化需要基于人群的深入探索和临床转化。癌症 2010；116：2549-59。 (C) 2010 年美国癌症协会。
BACKGROUND: Although US year 2000 guidelines recommended characterizing breast cancers by human epidermal growth factor receptor 2 (HER2), national cancer registries do not collect HER2, rendering a population-based understanding of HER2 and clinical "triple subtypes" (estrogen receptor [ER] / progesterone receptor [PR] / HER2) largely unknown. We document the population-based prevalence of HER2 testing / status, triple subtypes and present the first report of subtype incidence rates. METHODS: Medical records were searched for HER2 on 1842 metropolitan Atlanta females diagnosed with breast cancer during 2003-2004. HER2 testing/status and triple subtypes were analyzed by age, race/ethnicity, tumor factors, socioeconomic status, and treatment. Age-adjusted incidence rates were calculated. RESULTS: Over 90% of cases received HER2 testing: 12.6% were positive, 71.7% negative, and 15.7% unknown. HER2 testing compliance was significantly better for women who were younger, of Caucasian or African-American descent, or diagnosed with early stage disease. Incidence rates (per 100,000) were 21.1 for HER2+ tumors and 27.8 for triple-negative tumors, the latter differing by race (36.3 and 19.4 for black and white women, respectively). CONCLUSIONS: HER2 recommendations are not uniformly adhered to. Incidence rates for breast cancer triple subtypes differ by age/race. As biologic knowledge is translated into the clinical setting eg, HER2 as a biomarker, it will be incumbent upon national cancer registries to report this information. Incidence rates cautiously extrapolate to an annual burden of 3000 and 17,000 HER2+ tumors for black and white women, respectively, and triple-negative tumors among 5000 and 16,000 respectively. Testing, rate, and burden variations warrant population-based in-depth exploration and clinical translation. Cancer 2010;116:2549-59. (C) 2010 American Cancer Society.